Sutro Biopharma (STRO) News Today → Biden replacement revealed? (From Paradigm Press) (Ad) Free STRO Stock Alerts $3.47 -0.25 (-6.72%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15msn.com - April 17 at 2:08 PMSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Buy" by Analystsamericanbankingnews.com - April 17 at 2:24 AMQ1 2024 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Increased by Analystmarketbeat.com - April 5 at 8:06 AMSutro Biopharma's (STRO) "Outperform" Rating Reaffirmed at Wedbushmarketbeat.com - April 3 at 1:34 PMTruist Financial Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $18.00marketbeat.com - April 3 at 10:18 AMSutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipelinemarkets.businessinsider.com - April 3 at 3:48 AMSutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantiallyfinance.yahoo.com - April 2 at 5:48 PMIpsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln Dealmarkets.businessinsider.com - April 2 at 7:47 AMIpsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADCmsn.com - April 2 at 7:47 AMSutro Biopharma Announces Pricing of $75 Million Underwritten Offeringglobenewswire.com - April 2 at 6:18 AMIpsen, Sutro Biopharma Enter Into Licensing Deal Valued at Up to $900 Mlnmarketwatch.com - April 2 at 2:46 AMIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsglobenewswire.com - April 2 at 1:00 AMPenny Stock Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech Investorsmsn.com - April 1 at 10:06 AMHC Wainwright Brokers Lower Earnings Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO)marketbeat.com - March 28 at 8:20 AMAnalysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)markets.businessinsider.com - March 27 at 2:09 PMNavigating 4 Analyst Ratings For Sutro Biopharmamarkets.businessinsider.com - March 27 at 9:09 AMSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advancesfinance.yahoo.com - March 27 at 9:09 AMOppenheimer Reaffirms "Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)marketbeat.com - March 27 at 8:29 AMSutro Biopharma (NASDAQ:STRO) Price Target Lowered to $8.00 at Wedbushmarketbeat.com - March 26 at 10:46 AMSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestonesfinanznachrichten.de - March 26 at 8:57 AMTD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)markets.businessinsider.com - March 26 at 3:56 AMSutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical Pipelinemarkets.businessinsider.com - March 26 at 3:56 AMSTRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 25 at 10:03 PMSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestonesglobenewswire.com - March 25 at 4:30 PMAdage Capital Partners GP L.L.C. Has $10.78 Million Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)marketbeat.com - March 9 at 6:36 AMRubric Capital Management LP Sells 703,934 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)marketbeat.com - March 6 at 6:45 AMSutro Biopharma, Inc. (NASDAQ:STRO) Stake Raised by Acadian Asset Management LLCmarketbeat.com - February 26 at 6:20 AMSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Updatemarketbeat.com - February 16 at 11:37 PMSutro Biopharma Expands Share Offering, Raises $129Mmsn.com - February 10 at 2:33 PMSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - February 2 at 1:20 AMSutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential Ambiguitiesmarkets.businessinsider.com - January 9 at 9:19 AMBuy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and Beyondmarkets.businessinsider.com - January 6 at 1:56 AMSutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by Wedbushmarketbeat.com - January 5 at 6:36 PMSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCfinance.yahoo.com - January 4 at 7:10 PMSutro Biopharma Stock (NASDAQ:STRO) Dividends: History, Yield and Datesbenzinga.com - December 29 at 11:25 PMSutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Toofinance.yahoo.com - December 18 at 8:54 AMSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024finance.yahoo.com - December 14 at 7:00 PMSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - December 14 at 1:30 AMBuy Rating for Sutro Biopharma: Promising Clinical Developments and Strategic Financial Strengthmarkets.businessinsider.com - December 12 at 2:44 PMSutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023finance.yahoo.com - December 11 at 6:16 PMSutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summitfinance.yahoo.com - December 4 at 7:47 PMAbbVie-ImmunoGen buyout deal lifts ADC-focused biotechsseekingalpha.com - December 1 at 7:35 AMAnalysts Are Bullish on Top Healthcare Stocks: G1 Therapeutics (GTHX), Sutro Biopharma (STRO)markets.businessinsider.com - December 1 at 1:47 AMVaxcyte Obtains Control Over Manufacturing & Development Of Cell-Free Extract For Vaccine Candidatesmarkets.businessinsider.com - November 27 at 11:44 PMVaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidatesfinance.yahoo.com - November 27 at 6:43 PMSutro Biopharma, Inc.: Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officerfinanznachrichten.de - November 23 at 9:47 AMSutro Biopharma Promotes Jane Chung to President and Chief Operating Officerfinance.yahoo.com - November 21 at 8:41 PMOptimistic Outlook on Sutro Biopharma: Solid Financials, Promising Drug Pipeline, and High Return Potential Fuel Buy Ratingmarkets.businessinsider.com - November 16 at 7:19 PMSutro Biopharma, Inc.: Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestonesfinanznachrichten.de - November 15 at 2:03 PMExpert Ratings for Sutro Biopharmamarkets.businessinsider.com - November 15 at 2:03 PM Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now STRO Media Mentions By Week STRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.690.43▲Average Medical News Sentiment STRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼02▲STRO Articles Average Week Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Coherus BioSciences News Adverum Biotechnologies News X4 Pharmaceuticals News Compass Therapeutics News Fennec Pharmaceuticals News Black Diamond Therapeutics News Elevation Oncology News Acumen Pharmaceuticals News Innate Pharma News Opthea News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
